Supplementary Figure S1. Schematic of the study design for (**A**) patients with IPF; (**B**) patients with SSc-ILD; and (**C**) patients with PPF.



*The date nintedanib became commercially available. †The date nintedanib was approved for SSc-ILD. ‡The date nintedanib was approved for PF-ILD.

CTD, connective tissue disease; IPF, idiopathic pulmonary fibrosis; PF-ILD, progressive fibrosing-interstitial lung disease; PPF, progressive pulmonary fibrosis; SSc-ILD; systemic sclerosis-interstitial lung disease.

Supplementary Figure S2. Patient flow diagram for (**A**) nintedanib users in patients with IPF; (**B**) pirfenidone users in patients with IPF; (**C**) nintedanib users in patients with PPF; (**D**) users of oral and IV glucocorticoids/immunosuppressive drugs/DMARDs for ILD treatment in patients with PPF; (**E**) nintedanib users in patients with SSc-ILD; and (**F**) users of oral and IV glucocorticoids/immunosuppressive drugs/DMARDs for ILD treatment in patients with SSc-ILD.




C
Patients included in the MDV database
N=43,154,754
Patients prescribed nintedanib
n=8,973
Excluding patients prescribed nintedanib before 29 May 2020
n=7,151
Patients with extractable baseline data for ≥6 months pre-index (baseline period) and ≥2 months post-index (follow-up period)
n=4,578
Patients with fibrosing ILD ICD-10 disease codes within 6 months before/on the index date
n=4,491
Patients aged ≥20 years on the index date
n=4,488
Excluding patients with only IPF disease codes, without any fibrosing ILD disease codes other than IPF and/or any underlying disease codes within 6 months before/on the index date
Final cohort: N=4,160
Autoimmune-related ILD subgroups:
SSc-ILD (n=524); MCTD-ILD (n=59); PM/DM-ILD (n=427); RA-ILD (n=114); SLE-ILD (n=223); Sjögren ILD (n=213); other autoimmune ILD (n=301)
Non-autoimmune-related ILD subgroups:
Exposure-related ILD (n=50); HP (n=152); sarcoidosis (n=52); unclassifiable IIP (n=2,577); iNSIP (n=64); other ILD (n=64)
D
Patients included in the MDV database
N=43,154,754
Patients prescribed oral and IV injectable glucocorticoids/ immunosuppressive drugs/anti-CTD drugs for ILD treatment
n=2,035,603
Excluding patients prescribed these drugs before 29 May 2020
n=1,518,712
Patients with extractable baseline data for ≥6 months pre-index (baseline period) and ≥2 months post-index (follow-up period)
n=485,177
Patients with fibrosing ILD ICD-10 disease codes within 6 months before/on the index date
n=19,102
Patients aged ≥20 years on the index date
n=19,071
Excluding patients with only IPF disease codes, without any fibrosing ILD disease codes other than IPF and/or any underlying disease codes within 6 months before/on the index date
Final cohort: N=18,403
Autoimmune-related ILD subgroups:
SSc-ILD (n=599); MCTD-ILD (n=117); PM/DM-ILD (n=824); RA-ILD (n=291); SLE-ILD (n=492); Sjögren ILD (n=678); other autoimmune ILD (n=806)
Non-autoimmune-related ILD subgroups:
Exposure-related ILD (n=332); HP (n=297); sarcoidosis (n=270); unclassifiable IIP (n=12,480); iNSIP (n=294); other ILD (n=2,453)



CTD, connective tissue disease; HP, hypersensitivity pneumonitis; ICD-10, International Classification of Diseases-10th Revision; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; iNSIP, idiopathic nonspecific interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; IV, intravenous; MCTD, mixed connective tissue disease; MDV, Medical Data Vision; PM/DM, polymyositis/dermatomyositis; PPF, progressive pulmonary fibrosis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.

Supplementary Figure S3. Number of drugs for ILD treatment concomitant with antifibrotics at the time of initiation of antifibrotic treatment by underlying disease.



Statistic	Nintedanib users in patients with PPF						
	Exposure-related ILD	HP	MCTD-ILD	Other auto-immune ILD	Other ILD	PM/DM-ILD	RA-ILD
Mean (SD)	0.70 (0.68)	0.78 (0.74)	1.4 (0.83)	1.2 (0.89)	0.84 (0.72)	1.6 (1.0)	1.5 (0.92)
Median (IQR)	1 (0–1)	1 (0–1)	1 (1–2)	1 (0–2)	1 (0–1)	2 (1–2)	2 (1–2)

Statistic	Nintedanib users in patients with PPF					
	SLE-ILD	SSc-ILD	Sarcoidosis	Sjögren ILD	Unclassifiable IIP	iNSIP
Mean (SD)	1.6 (0.90)	0.97 (0.90)	0.67 (0.83)	1.1 (0.91)	0.41 (0.63)	0.80 (0.78)
Median (IQR)	2 (1–2)	1 (0–2)	0 (0–1)	1 (0–2)	0 (0–1)	1 (0–1)

HP, hypersensitivity pneumonitis; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; iNSIP, idiopathic nonspecific interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; IQR, interquartile range; MCTD, mixed connective tissue disease; PM/DM, polymyositis/dermatomyositis; RA, rheumatoid arthritis; SD, standard deviation; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.

Supplementary Figure S4. Number of drugs for ILD treatment prior to the initiation of antifibrotics by underlying disease..



Statistic	Nintedanib users in patients with PPF						
	Exposure-related ILD	HP	MCTD-ILD	Other auto-immune ILD	Other ILD	PM/DM-ILD	RA-ILD
Mean (SD)	0.74 (0.92)	0.80 (0.79)	1.4 (0.91)	1.3 (1.1)	0.88 (0.83)	1.7 (1.2)	1.7 (1.2)
Median (IQR)	1 (0–1)	1 (0–1)	1 (1–2)	1 (0–2)	1 (0–1)	2 (1–2)	2 (1–2.75)

Statistic	Nintedanib users in patients with PPF					
	SLE-ILD	SSc-ILD	Sarcoidosis	Sjögren ILD	Unclassifiable IIP	iNSIP
Mean (SD)	1.8 (1.2)	1.0 (1.0)	0.62 (0.87)	1.1 (1.0)	0.44 (0.69)	0.78 (0.74)
Median (IQR)	2 (1–2)	1 (0–2)	0 (0–1)	1 (0–2)	0 (0–1)	1 (0–1)

HP, hypersensitivity pneumonitis; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease; iNSIP, idiopathic nonspecific interstitial pneumonia; IPF, idiopathic pulmonary fibrosis; IQR, interquartile range; MCTD, mixed connective tissue disease; PM/DM, polymyositis/dermatomyositis; RA, rheumatoid arthritis; SD, standard deviation; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.